Acquisition Pending Sponsor buyer
ARCHIMED acquisition of Esperion Therapeutics
US$1.1bn equity value
Announced 1 May 2026 · NASDAQ: ESPR · US$3.16 cash per share · 58% premium
Advisers
Esperion Therapeutics
Target
- Financial adviser
- Legal adviser
- Fairness opinion
Other advisers
- Legal adviser
- Target
- Esperion Therapeutics
- Acquirer
- ARCHIMED
- Target based in
- United States
- Buyer based in
- France
- Sector
- Pharma
- Tags
- Pharma, Cardiovascular
In the league tables
Similar deals
- Esperion Therapeutics acquisition of Corstasis Therapeutics Mar 2026 · US$75m · Pharma
- Zymeworks acquisition of Theravance Biopharma Jun 2026 · US$929m · Pharma
- Eli Lilly and Company acquisition of Ventyx Biosciences Jan 2026 · US$1.2bn · Biotech
- Veloxis Pharmaceuticals acquisition of AiCuris Anti-infective Cures AG Feb 2026 · US$913m · Pharma
- Otsuka acquisition of Transcend Therapeutics Mar 2026 · US$700m · Biotech
Sources
- 2026 Centerview Partners: Financial advisor to Esperion Therapeutics on its acquisition by ARCHIMED centerviewpartners.com
- 2026 Moelis & Company: Acquisition of Esperion moelis.com
- May 2026 Latham Advises on Esperion Acquisition by ARCHIMED lw.com
- 1 May 2026 Press release (EX-99.1, exhibit), Esperion to be Acquired by ARCHIMED sec.gov
- 1 May 2026 Goodwin Advises Esperion on $1.1 Billion Acquisition by ARCHIMED goodwinlaw.com
- 1 May 2026 Sidley Represents Archimed in US$1.1 Billion Acquisition of Esperion Therapeutics sidley.com
- 8 Jun 2026 Definitive merger proxy statement (DEFM14A), Esperion Therapeutics, Inc. sec.gov




